Shijiazhuang Yiling Pharmaceutical (002603.SZ): Withdrawal of the application for clinical trials of "G201-Na Capsules" medication.
Lingyun Pharmaceuticals (002603.SZ) announced that the company will follow the relevant drug approval policies and combine them with the progress of its research projects...
Shijiazhuang Yiling Pharmaceutical (002603.SZ) announced that, based on the relevant policies of drug approval and the progress of research projects, the company has decided, after careful consideration, to apply to the National Medical Products Administration (hereinafter referred to as "NMPA") to withdraw the clinical trial application for the drug "G201-Na Capsules" for the indication of "assisted reproduction". Recently, the company received the "Notice of Termination of Drug Registration Application" issued by the NMPA.
Related Articles
ANHUI EXPRESSWAY (00995) shareholder China Merchants Expressway Network & Technology Holdings has cumulatively reduced its holdings by approximately 8.409 million A shares. The reduction plan has been completed.
US Stock Market Move | Permira and Huaping Investment led the acquisition of Clearwater Analytics (CWAN.US), causing its pre-market stock price to surge over 8%.
Guangdong Shirongzhaoye (002016.SZ) plans to issue convertible bonds to raise funds of no more than 550 million yuan.
ANHUI EXPRESSWAY (00995) shareholder China Merchants Expressway Network & Technology Holdings has cumulatively reduced its holdings by approximately 8.409 million A shares. The reduction plan has been completed.
US Stock Market Move | Permira and Huaping Investment led the acquisition of Clearwater Analytics (CWAN.US), causing its pre-market stock price to surge over 8%.
Guangdong Shirongzhaoye (002016.SZ) plans to issue convertible bonds to raise funds of no more than 550 million yuan.
